A comparison of SARS-COV-2 neutralizing antibody therapies in high-risk patients with mild to moderate COVID-19 disease at a single academic hospital
DA Farcy, MT Dalley, G Miro, P Swalley… - The Journal of …, 2022 - Elsevier
Background: Bamlanivimab and casirivimab/imdevimab are recombinant neutralizing
monoclonal antibodies that decrease viral load in patients with coronavirus disease 2019 …
monoclonal antibodies that decrease viral load in patients with coronavirus disease 2019 …
French pharmacovigilance survey of casirivimab-imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
C de Canecaude, F Montastruc, S Bergeron… - Therapies, 2023 - Elsevier
Summary Introduction Casirivimab and imdevimab (Ronapreve®) are two recombinant
human monoclonal antibodies (mAbs) that bind to the severe acute respiratory syndrome …
human monoclonal antibodies (mAbs) that bind to the severe acute respiratory syndrome …
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients-mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19–Repurposed Drugs …
S Kulkarni, M Fisk, M Kostapanos, E Banham-Hall… - Trials, 2020 - Springer
Objectives To determine if a specific immunomodulatory intervention reduces progression of
COVID-19-related disease to organ failure or death, compared to standard of care (SoC) …
COVID-19-related disease to organ failure or death, compared to standard of care (SoC) …
COVID-19 Pharmacotherapy: A Summary of Key Advances and Insights from the Special Issue
G Schinas, K Akinosoglou - Viruses, 2023 - mdpi.com
The COVID-19 pandemic has presented unprecedented challenges for healthcare systems
worldwide. Beyond the development of vaccines, discovering effective pharmacotherapies …
worldwide. Beyond the development of vaccines, discovering effective pharmacotherapies …
REGEN-COV antibody combination and outcomes in outpatients with Covid-19
DM Weinreich, S Sivapalasingam… - … England Journal of …, 2021 - Mass Medical Soc
Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …
[PDF][PDF] Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
JJJMH Vera, MRJ Sanchez, DWDML Farinas, J Bussey - 2022 - scienceopen.com
Introduction: Data on real-world effectiveness of subcutaneous(SC) casirivimab and
imdevimab (CAS? IMD) for the treatment of coronavirus disease 2019 (COVID-19) are …
imdevimab (CAS? IMD) for the treatment of coronavirus disease 2019 (COVID-19) are …
Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 …
MP O'Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou… - Jama, 2022 - jamanetwork.com
Importance Easy-to-administer anti–SARS-CoV-2 treatments may be used to prevent
progression from asymptomatic infection to symptomatic disease and to reduce viral …
progression from asymptomatic infection to symptomatic disease and to reduce viral …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Association of intravenous bamlanivimab use with reduced hospitalization, intensive care unit admission, and mortality in patients with mild to moderate COVID-19
Background Clinical data to support the use of bamlanivimab for the treatment of outpatients
with mild to moderate coronavirus disease-19 (COVID-19) is needed. Methods 2,335 …
with mild to moderate coronavirus disease-19 (COVID-19) is needed. Methods 2,335 …
Casirivimab+ imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of …
syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of …